Provided by Tiger Fintech (Singapore) Pte. Ltd.

Summit Therapeutics PLC

27.07
+0.70002.65%
Post-market: 27.300.2300+0.85%19:59 EDT
Volume:1.92M
Turnover:51.12M
Market Cap:20.10B
PE:-79.72
High:27.44
Open:25.86
Low:25.41
Close:26.37
Loading ...

BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors

Reuters
·
30 Jun

Cantor Fitzgerald Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
24 Jun

Summit Therapeutics Inc. Secures Sub-Sublease Agreement for New Office Space in Palo Alto

Reuters
·
21 Jun

Summit Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
18 Jun

Summit Therapeutics (SMMT) Gets a Buy from Evercore ISI

TIPRANKS
·
16 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Vaxart, DoubleVerify, Cracker Barrel

Reuters
·
12 Jun

US STOCKS-S&P 500, Nasdaq set to open near record levels after May inflation data

Reuters
·
11 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Quantum computing stocks, Grab Holdings, Talen Energy

Reuters
·
11 Jun

BUZZ-Summit slips as Leerink doubts cancer drug can match Keytruda's success

Reuters
·
11 Jun

Summit Therapeutics Announces Inducement Grants for New Employees Under Nasdaq Rule

Reuters
·
07 Jun

Summit Therapeutics Inc. to Present at 46th Annual Goldman Sachs Global Healthcare Conference in Miami

Reuters
·
05 Jun

Truist Financial Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
03 Jun

Cantor Fitzgerald Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-RBB Bancorp, Seacoast, GATX

Reuters
·
31 May

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. -- Barrons.com

Dow Jones
·
30 May

Summit Says Ivonescimab Significantly Improves Progression-Free Survival; Overall Survival Trend Not Statistically Significant -- Shares Drop

MT Newswires Live
·
30 May

BUZZ-Summit Therapeutics falls after mixed data from late-stage cancer trial

Reuters
·
30 May

Summit Therapeutics announces topline results from Phase 3 HARMONi trial

TIPRANKS
·
30 May

Summit Therapeutics initiated with a Buy at Clear Street

TIPRANKS
·
22 May

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

Dow Jones
·
20 May